Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 2;42(25):3033–3046. doi: 10.1200/JCO.23.02233

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 1. — Antitumor activity and response by measurable disease. (A) Waterfall plot of change in target lesions from baseline. Horizontal upper and lower dashed lines represent RECIST boundaries of 20% increase and 30% decrease in size of target lesions, respectively. (B) Waterfall plots for renal cell carcinoma, urothelial carcinoma, and prostate cohorts. Tumor type for each cohort is listed for each group. (C) Waterfall plots for adenocarcinoma, squamous cell carcinoma of the bladder/urinary tract, small cell carcinoma of the bladder/urinary tract, penile carcinoma, and germ cell tumor cohorts. Tumor type for each cohort is listed for each group. (D) Waterfall plot for rare genitourinary tumor cohort. Tumor type for each individual is listed above each bar. (E) Swimmer's plot showing duration of response, treatment arm, and response. (F) Spider plot depicting response and change in target lesion size (tumor burden) from baseline for individual participants. Red bars/lines represent PD, yellow bars represent SD, green bars represent PR, and blue bars represent CR as best response. CaboNivo, cabozantinib + nivolumab; CaboNivoIpi, cabozantinib + nivolumab + ipilimumab; CR, complete response; PR, partial response; SD, stable disease.